For novel technologies like photobioreactors, infrastructure is scarce. Companies must partner with separate CMOs for upstream cultivation and downstream processing to reach initial commercial revenue before building their own integrated facilities.

Breakthroughs in bioprocessing occur at the intersection of molecular biology and process engineering. The most effective approach is an iterative cycle: engineer a strain for specific process needs, test it in a real bioreactor (not just a flask), and use that performance data to inform the next round of strain improvement.

The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.

The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.

To make commodity products like cocoa economically viable, California Cultured rejects expensive stainless-steel bioreactors (costing up to $1M). Instead, they use simple plastic tanks costing only a few thousand dollars. This drastically reduces CapEx and is a fundamental shift in biomanufacturing philosophy for low-margin goods.

The primary value of AI in bioprocessing is not just automating tasks, but analyzing process data to predict outcomes. This requires a fundamental shift in capital equipment design, focusing on integrating more sensors and methods to collect far more granular data than is standard today.

Unlike traditional fermentation where moving to larger tanks introduces significant process variability, photosynthetic systems using photobioreactors scale modularly. Companies can simply add more units ("scaling out"), which minimizes performance differences and de-risks the transition to commercial-scale manufacturing.

Continuous microbial manufacturing lags behind mammalian systems primarily due to the high replication rate of microbes like E. coli, which causes rapid genetic drift and loss of productivity. The solution is biological, not mechanical: decoupling cell growth from protein production to genetically stabilize the system for long-duration runs.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.